EGFR and oral cavity squamous cell carcinoma: For CAP-based therapies, if the interactions between EGFR and CAP-induced radicals lead to degradation and dysfunction of the EGFR, a combination of CAP treatment and conventional EGFR-targeted therapy is suggested as novel therapeutic means of preventing or overcoming secondary resistance in oral squamous cell carcinoma cells [33].